ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SYNC Syncona Limited

120.40
-1.60 (-1.31%)
Last Updated: 09:24:23
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.60 -1.31% 120.40 120.20 121.60 122.20 120.20 122.20 35,167 09:24:23
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Trust,ex Ed,religious,charty -39.79M -56.02M -0.0840 -14.31 801.41M

Syncona 3Q Net Asset Value Rose; Portfolio Companies Continued to Attract Capital

10/02/2022 9:26am

Dow Jones News


Syncona (LSE:SYNC)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Syncona Charts.

By Anthony O. Goriainoff

 

Syncona Ltd. said on Thursday that its net asset value rose 16% in the third quarter compared with the previous quarter, and that its portfolio companies continued to attract substantial capital in the period.

The London-listed life-sciences investment company said net assets at Dec. 31 were 1.34 billion pounds ($1.81 billion) compared with GBP1.15 billion on Sept. 30.

The company said it received five significant financing commitments in the period ended Dec. 31 totaling $674 million of capital across Autolus, Quell, Anaveon, Gyroscope and Clade.

The company said it expects the forthcoming sale of portfolio company Gyroscope Therapeutics to Novartis AG to deliver a GBP221 million uplift to net asset value. The company said it anticipates upfront proceeds on closing to be GBP326.7 million.

Syncona said in December that Novartis had agreed to acquire Gyroscope for up to $1.5 billion.

"Many of our companies are approaching clinical data readouts in the next 12 months, and we remain confident in the potential of our portfolio to drive value and deliver transformational treatments to patients," Chief Executive Martin Murphy said.

Shares at 0845 GMT were up 6.80 pence, or 3.5%, at 202 pence.

 

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

 

(END) Dow Jones Newswires

February 10, 2022 04:11 ET (09:11 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

1 Year Syncona Chart

1 Year Syncona Chart

1 Month Syncona Chart

1 Month Syncona Chart

Your Recent History

Delayed Upgrade Clock